Related by context. All words. (Click for frequent words.) 66 selective modulator 66 CD8 T cell 65 aberrant immune 64 factor TNF 64 5 HT6 receptor 63 immunostimulatory 63 serum antibody 63 mitogenic 63 antitumor immune 62 D aspartate NMDA receptor 62 tipranavir ritonavir 62 IFN γ 62 TLR antagonist 62 novel VDA molecule 62 pDCs 61 humoral antibody 61 demonstrated antitumor activity 61 cytotoxic antibody 61 interleukin IL -# 61 basophils 61 ALB # 61 interferon γ 61 Known hypersensitivity 61 methyl D aspartate 61 dose proportionality 61 adrenoceptor 61 CCR2 60 hemagglutination inhibition HAI 60 K ras mutations 60 GPIIb IIIa 60 soluble TNF receptor 60 concomitantly administered 60 potent antitumor activity 60 receptor inhibitor 60 tumorigenicity 60 Akt activation 60 cAMP signaling 60 γ secretase 60 IAP inhibitor 60 plasma pharmacokinetics 59 HCV protease 59 bortezomib refractory 59 5 HT2A receptor 59 pegylated alpha interferon 59 cisplatin resistant 59 acoustic startle 59 alpha TNF 59 EGFRvIII 59 muscarinic 59 antitumoral 59 chemokine receptor 59 ERK1 2 59 Th2 immune 59 chimeric monoclonal antibody 59 antifibrotic 59 IL 1ß 59 alpha#beta# integrin 59 florbetaben 59 thrombin receptor 59 receptor CXCR4 59 Sphingomab 59 pharmacodynamic mechanism 59 TNFalpha 59 alpha 2A 59 antiangiogenic 59 nicotinic acetylcholine 59 pathophysiological effects 59 adrenocorticotropic hormone 59 androgen receptor AR 58 mediated inhibition 58 TNF α 58 effector function 58 antiangiogenic therapy 58 siRNA mediated 58 potent inducer 58 isoproterenol 58 small molecule Hedgehog 58 gonadotrophin releasing hormone GnRH 58 E#F# 58 immunological responses 58 cytotoxic T lymphocyte 58 5 HT2A 58 MDR1 58 IFN g 58 5alpha reductase 58 ChR2 58 HLA DR4 immune 58 IGF IR 58 evaluating Prochymal 58 subcutaneously administered 58 nicotinic 58 AT1R 58 inverse agonist 58 preclinical pharmacokinetic 58 5 HT1A 58 somatostatin 58 5 HT1A receptor 58 Î ² 58 cytostatic 58 neutralizing antibody responses 58 EBMT criteria 58 HLA DR2 58 VEGF receptor 58 5 HT4 receptor 58 estrogen receptor beta 58 interleukin 1ß 58 Topoisomerase II 58 relapsed MCL 58 achieve sustained virologic 58 pharmacodynamic effects 58 cytoprotective 58 neuroinflammatory 58 preclinical efficacy 58 mitogen activated protein kinases 58 downregulated 57 selective agonists 57 enkephalin 57 bafetinib demonstrated 57 5 HT4 57 neuroregenerative 57 peripheral blood mononuclear 57 endothelin receptor 57 humoral 57 Hepatotoxicity 57 Y2 receptor 57 tumor necrosis 57 pegylated 57 mu opioid 57 cytokine signaling 57 tryptase 57 4 PDE4 enzyme 57 prostaglandin E2 PGE2 57 opinion@dailycardinal.com 57 HIF 1alpha 57 Selective Inhibitor 57 trastuzumab resistant 57 antisense inhibition 57 selective antagonist 57 Th2 cytokines 57 Akt inhibitor 57 dose dependently 57 CORT # 57 nucleoside analogues 57 retinal ischemia 57 anaphylactic reactions bronchospasm 57 allergic airway inflammation 57 microglial activation 57 aT cell 57 potent inhibitor 57 mucosal immune 57 dopamine D2 57 tyrosine kinase inhibitor 57 calcitonin gene related 57 potent antiproliferative 57 PC# cells 57 2A receptor agonist 57 gonadotropin releasing hormone GnRH 57 N methyl 56 Solid Tumors criteria 56 nicotinic acetylcholine receptor 56 molecular determinants 56 hyperalgesia 56 mitogen activated protein kinase 56 TLR9 56 Kinoid 56 PTP 1B 56 potentiation 56 c Src 56 selective serotonin 2C receptor 56 selectively inhibits 56 proteasome inhibitor 56 AEG# 56 MVA MUC1 IL2 56 gonadotrophin releasing hormone 56 CD#c 56 adenosine A2A 56 TriGrid ™ 56 aminotransferase levels 56 vascular disrupting 56 hematologic cytogenetic 56 FK# 56 histone deacetylase HDAC 56 lenalidomide dexamethasone 56 humanized monoclonal antibodies 56 PI3K/mTOR 56 #mg BID [002] 56 TNFα 56 anti inflammatory cytokine 56 serum HBV DNA 56 COX2 56 GSK3B 56 selective agonist 56 Pharmacodynamic 56 Janus kinase 56 constitutively active 56 upon rechallenge 56 downstream effectors 56 delta opioid receptor 56 innate immune responses 56 fulvestrant 56 ERK activation 56 phosphate S1P 56 cytotoxin 56 uPAR 56 MAPK pathway 56 NOD mice 56 Virological 56 prodrugs 56 factor Xa 56 hCG beta 56 bispecific 56 transfected cells 56 vasodilatory 56 thyroid hormone receptor 56 endogenous opioid 56 progesterone receptor 56 hypermethylated 56 sodium glucose cotransporter 56 antidiabetic 56 monoclonal antibody mAb 56 linear pharmacokinetics 56 hypercalcemia 56 eotaxin 56 cytokines IL 55 partial agonist 55 FGFR 55 patients evaluable 55 HBsAg 55 deacetylation 55 targeting PCSK9 55 ischemia induced 55 motesanib 55 Pharmacokinetic parameters 55 endogenous ligands 55 opioid antagonist 55 Valproic acid 55 Th1 cells 55 serotonin receptor 55 antagomirs 55 vivo coagulation 55 mTOR inhibitors 55 Severe infusion 55 bronchoalveolar lavage fluid 55 Aldosterone 55 potentiated 55 cyclic nucleotide 55 peptidic 55 upregulates 55 CXCL# 55 BMS # 55 pleiotropic 55 overactivated 55 A3 adenosine receptor 55 NR2B selective 55 Gamma interferon 55 small molecule agonists 55 C5aR 55 MT1 MMP 55 annexin 55 achieving sustained virologic 55 LC#m# vaccine 55 CYP#D# inhibitors 55 alpha2 55 Secondary endpoints include 55 Hypoxia Inducible Factor 55 PU H# 55 reversible inhibitor 55 angiotensin receptor 55 neurokinin 1 55 beta1 integrin 55 CD8 cell 55 glucagon receptor 55 #HT# 55 5HT 55 recurrent genital herpes 55 Tannah Hirsch welcomes 55 beta lactam antibiotic 55 FLT3 ITD 55 IFN alpha 55 DNA hypermethylation 55 imatinib therapy 55 IL 6R 55 5 lipoxygenase 55 included exfoliative dermatitis 55 somatostatin receptors 55 downregulating 55 p# Shc 55 VEGF receptors 55 autoreactive 55 RECIST Response Evaluation Criteria 55 GABA aminotransferase 55 TNF receptors 55 IGF 1R 55 corticosteroids immunoglobulins 55 receptor blocker 55 serum antibodies 55 pharmacokinetic parameters 55 c MYC 55 Notch receptors 55 oncogenic transformation 55 angioneurotic edema 55 mGluR2 NAM 55 PPARg 55 potent inhibitors 55 cyclooxygenase 55 molecular remissions 55 p# activation 55 antibody responses 55 telomerase inhibition 55 CK2 55 bicalutamide 55 survivin 55 TRPV1 receptors 55 oncogenic signaling 54 pulmonary inflammation 54 antiproliferative effects 54 JAK#/JAK# 54 EMBLEM ™ 54 NK 1R 54 splenectomized patients 54 5 HT3 receptor 54 lysyl oxidase 54 biased ligand 54 antiinflammatory 54 lysophosphatidic acid LPA 54 HBV replication 54 topoisomerase II 54 TMPRSS2 ERG fusion 54 prostaglandin synthesis 54 dual orexin receptor 54 agonists antagonists 54 Dendritic cell 54 demyelinating disease 54 #HT# receptor 54 neuronal nicotinic receptor NNR 54 virologic responses 54 retinoic acid receptor 54 overactivation 54 antiarrhythmic 54 mGluR5 antagonist 54 IgE mediated 54 immune effector 54 Immunohistochemical 54 immunomodulatory 54 muscarinic receptors 54 Interferon alpha 54 severe hypersensitivity reactions 54 Epothilones 54 thermal hyperalgesia 54 dose escalation phase 54 drug metabolizing enzymes 54 lymphomas leukemias 54 mineralocorticoid 54 glucocorticoid receptors 54 c Fos 54 costimulation 54 pharmacodynamic biomarkers 54 ornithine decarboxylase 54 pharmacokinetic characteristics 54 -#.# log# copies mL 54 humoral immune responses 54 CD# monoclonal antibody 54 Panzem R NCD 54 ENaC 54 herpes virus infections 54 interferon induced 54 serine protease 54 PENNVAX B 54 miR #b [002] 54 SIRT2 54 humoral responses 54 glucose intolerant 54 Th2 responses 54 NKG2D 54 rhEPO 54 #ME# 54 tumor regressions 54 myeloproliferative diseases 54 Androgen receptor 54 #HT#A 54 kappa opioid receptor 54 antimitotic 54 intermittent dosing 54 p#Kip# 54 leukotriene 54 KRAS status 54 Neuropeptide Y 54 apoptosis induced 54 cortisol receptor 54 inactivated influenza virus 54 tolerability profiles 54 thymidylate synthase TS 54 resolvins 54 NS4A 54 related apoptosis inducing 54 proapoptotic 54 receptor antagonists 54 ERK phosphorylation 54 receptor subtypes 54 chemopreventive agent 54 CXCR2 54 carbonic anhydrase inhibitors 54 neuroprotective properties 54 intravascular hemolysis 54 TNF á 54 HSP# inhibitor 54 genotoxic stress 54 ligand TRAIL 54 immunoregulatory 54 CDKN2A 54 Tumour Necrosis Factor 54 5 HT2C 54 immunoreactivity 54 cathepsins 53 thrombopoietin 53 Milatuzumab 53 Rate ORR 53 vascular disrupting agents 53 GeoVax HIV AIDS 53 dopamine D1 53 RUNX3 53 receptor agonists 53 immune stimulatory 53 adenosine receptor 53 HDAC enzyme 53 glucocorticoid receptor 53 bexarotene 53 peptide CGRP 53 CCR7 53 nucleoside analogs 53 effector T 53 receptor partial agonist 53 HMG CoA reductase inhibitors 53 mecamylamine 53 inhibiting COX 53 sphingosine 1 53 cyclin dependent kinase inhibitor 53 LNCaP cells 53 chemokine 53 bispecific antibody 53 Innate immune 53 GLUT1 53 Preclinical studies suggest 53 TNF inhibitor 53 siRNA therapeutic 53 IRS1 53 ErbB receptors 53 TNF IL 53 Primary endpoints 53 liver transaminases 53 detectable HCV RNA 53 vitro experiments 53 kainate 53 nonnucleoside reverse transcriptase inhibitors 53 SIRT1 activators 53 parkinsonian symptoms 53 Vaxfectin TM formulated 53 DNMT1 53 GLI1 53 AKT pathway 53 habenula 53 LPA1 receptor 53 excitotoxic 53 negative allosteric modulator 53 subcutaneous PRO 53 MAPKs 53 Hematologic toxicity 53 Vaxfectin R formulated 53 quantitative polymerase chain 53 FasL 53 autoreactive T cells 53 BN# [002] 53 cerebral ischemia 53 CRTH2 53 JAK inhibitors 53 receptor agonist 53 unprintable elicited different 53 pancreatic prostate 53 suppressor cells 53 Tumor regression 53 heme oxygenase 53 cytopenia 53 NMDA N 53 idarubicin 53 signal transduction inhibitor 53 tropomyosin 53 NAbs 53 ouabain 53 multitargeted 53 BCR ABL protein 53 thyroid peroxidase 53 resistant mutants 53 oncoproteins 53 agonist antagonist 53 TLR3 53 ATPace TM 53 imatinib Gleevec 53 kinase inhibition 53 inhibit tumor angiogenesis 53 pancytopenia 53 CTLA 4 53 nonclinical studies 53 Vpu 53 immune suppressive 53 amyloid cascade 53 cyclooxygenase 2 53 pharmacodynamic endpoints 53 microRNA antagonists 53 IgG4 53 protein phosphatase 53 Pharmacokinetic studies 53 bone morphogenetic proteins BMPs 53 EXJADE 53 beta adrenergic receptors 52 receiving XGEVA 52 coexpression 52 CYP#D# inhibitor 52 Notch1 52 MERIT ES 52 TRPA1 receptor 52 rituximab monotherapy 52 Adenosine A2A 52 reverse transcriptase polymerase chain 52 mGluR4 52 CR CRu 52 catenin 52 NPM1 mutations 52 Tumor necrosis factor 52 autoinflammatory diseases 52 nicotinic receptor 52 EGFR inhibitors 52 globulins 52 inhibitory effect 52 secondary bacterial pneumonia 52 p# mitogen activated 52 InTheNews.co.uk brings 52 small molecule VR1 52 GABA receptor 52 hepatotoxic 52 synovial cells 52 Active Ulcerative Colitis 52 inflammatory cytokines TNF 52 demonstrated clinically meaningful 52 B7 H4 52 CTLs 52 upregulate 52 superoxide anion 52 peroxisome proliferator activated 52 RANK Ligand 52 HER2 neu 52 hematopoietic cancers 52 Jurkat cells 52 HuLuc# 52 androgen receptor pathway 52 glutamyl 52 noxious stimuli 52 Immune responses 52 CD8 T cells 52 akinetic mutism 52 Subgroup analysis 52 somnolence dizziness 52 corticosteroid therapy 52 urticaria hives 52 GPR# [002] 52 interleukin IL 52 cyclic peptide 52 alpha TNF alpha 52 Progressive Multifocal Leukoencephalopathy PML 52 Angiotensin II 52 alpha adrenergic 52 #beta HSD 1 52 peptide hormone 52 CaM 52 pulmonary infiltrates 52 tumor vasculature 52 histamine receptor 52 neointimal hyperplasia 52 SGLT2 52 transmembrane protein 52 chemokine SDF 1 52 agonism 52 receptor PPAR 52 monoinfected patients 52 Raf kinase 52 modulatory 52 cellular prion protein 52 QOTD sent 52 CD# antibodies 52 pharmacodynamics PD 52 antiepileptics 52 receptor mediated 52 5 HT2C receptor 52 lymphocyte counts 52 oxidative metabolism 52 PCNSL 52 SNP rs# [002] 52 anti HBc 52 3'UTR 52 dipeptidyl peptidase IV 52 Gilead Viread 52 immunostimulatory effects 52 protein kinase C 52 XL# SAR# 52 selectively inhibit 52 receptor activator 52 cerebral ischemic 52 histone deacetylase inhibitors 52 CB2 receptor 52 chemosensitivity 52 Boron disrupts nuclear 52 insertional mutagenesis 52 Curaxins 52 agonist compounds 52 mTOR signaling 52 inhibitory effects 52 interferon beta 52 prodromal phase 52 embryonal carcinoma 52 kinesin spindle protein KSP 52 monocyte chemoattractant protein 52 beta adrenergic 52 PD L1 52 subtype selective 52 AMPK activators 52 interferons 52 intratumoral 52 serine proteases 52 autoimmune reactions 52 humoral immune response 52 KSP inhibitor 52 darbepoetin alpha 52 pharmacologic 52 ELISpot 52 ricin neutralizing antibodies 52 TLR2 52 intracoronary infusion 51 monoclonal antibody Rituxan 51 E selectin 51 adenovirus mediated 51 TG# [003] 51 receptor subunits 51 Angiotensin 51 potentiates 51 effector molecules 51 KLF4 51 JAK1 51 lateral habenula 51 epithelial markers 51 proteasome inhibitors 51 anti HBs 51 rs# [004] 51 VEGF inhibitors 51 scintigraphic 51 CB2 receptor selective 51 virological response 51 laxative therapy 51 IgE antibodies 51 Histologic 51 painful stimuli 51 VMAT2 51 serotonin reuptake inhibitor 51 Pharmacokinetic PK 51 HUMIRA resembles 51 prostacyclin receptor 51 experimentally validated 51 poststroke depression 51 bromocriptine 51 PPARγ 51 DNA demethylation 51 clinicopathological 51 rituximab refractory 51 histone deacetylases 51 RECIST criteria 51 Onyx Pharmaceuticals Announces 51 relapsers 51 topoisomerase 51 proinflammatory cytokine 51 phosphatases 51 JAK inhibitor 51 Cre recombinase 51 receptor antagonist 51 refractory prostate cancer 51 coinfected patients 51 CENP E 51 dose proportional pharmacokinetics 51 immunomodulatory effects 51 Pharmacokinetic 51 opioid peptides 51 TGF beta signaling 51 live attenuated vaccines 51 TNF blocker therapy 51 partial agonists 51 beta arrestin 51 NF kappaB 51 hepatic toxicity 51 effector cells 51 4CMenB 51 adrenoreceptor 51 histone deacetylase 51 CaMKII 51 Leukotriene 51 CRTC3 51 immunologic responses 51 anti fibrotic 51 enzyme inhibitor 51 5 HT4 agonist 51 GABAA receptors 51 glutamate receptors 51 selective estrogen receptor modulator 51 neuropilin 51 costimulatory 51 invading pathogen 51 autonomic arousal 51 hematological parameters 51 histologic findings 51 COX enzymes 51 GlcNAc 51 previously uncharacterized 51 tumor histology 51 Hsp# chaperone system 51 #HT#A receptor 51 CGRP 51 IgG isotype 51 MMP2 51 SGS# 51 transient receptor 51 follicular Non Hodgkin 51 VE cadherin 51 autoantibody levels 51 neurokinin 51 adenosine receptors 51 Suicidal ideation 51 pathway inhibitor 51 myoclonus 51 JAK2 inhibitors 51 anti angiogenic 51 receptor modulators 51 PI3 kinase 51 GABAB receptors 51 renoprotective 51 PKC inhibitor 51 selective inhibitors 51 mRNA antagonist 51 selective adenosine 51 COX inhibitors 51 DuraSite ® 51 JNK1 51 endocrine tumors 51 EGFR antibodies 51 BRAF mutations 51 Cockpit distractions 51 type glutamate receptor 51 viral antigens 51 adrenergic 51 immunologically 51 antisense compounds 51 CD#b 51 GABRA2 51 placebo controlled clinical trials 51 basiliximab 51 aminopeptidase 51 mg/m2 cohort 51 receptor subtype 51 isoenzymes 51 NMDA receptor antagonist 51 anti EGFR monoclonal 51 vagal 51 locomotor activity 51 CRu 51 dopaminergic 51 incretin 51 RASSF1A 51 anti nogo 51 antimetastatic 50 long acting muscarinic 50 estrogen receptor ER 50 analgesic effects 50 EEG abnormalities 50 kallikrein 50 GnRH receptor 50 sublethal 50 arginine vasopressin 50 bronchial epithelial cells 50 phospholipase 50 Ebola SNALP 50 echinocandins 50 vanilloid receptor 50 insulin sensitizers 50 meta regression 50 leukotriene B4 LTB4 50 ORAL Solo 50 histologic subtypes 50 nonresponders 50 prognostic markers 50 anticholinergic effects 50 clinicopathological features 50 oxytocin receptor 50 oral hyoscyamine spray 50 2A/Furin technology 50 Pharmacologic 50 subcutaneous formulation 50 cyclophilin D 50 Nrf2 gene 50 Chlamydia trachomatis infection 50 TRIM5a 50 antidepressant efficacy 50 airway narrowing 50 Tissue Factor 50 carboplatin Taxol 50 inhibitory neurotransmitters 50 AST ALT 50 USP# 50 5 HT2B receptor 50 extracellular dopamine 50 dimerization 50 synthetic analogues 50 potently inhibits 50 gyrase 50 alpha syn 50 Nedd4 50 cannabinoid receptor 50 homologues 50 inhibition 50 Wnt signaling pathway 50 asthma immunotherapeutic 50 IgM 50 Agonist 50 neointimal proliferation 50 SGLT2 inhibitors 50 plasma lipoprotein 50 RANK ligand 50 luciferin 50 hyperactivated 50 intact parathyroid hormone 50 receptor gene 50 paroxysmal supraventricular tachycardia 50 pain tenderness induration 50 N Myc 50 oral inducer 50 synthetic retinoid 50 Serum concentrations 50 targeting refractory relapsing 50 allodynia 50 Src kinase 50 glutamate signaling 50 SNP rs# [001] 50 immune suppressing 50 adrenergic receptor 50 AVI NEUGENE 50 cytologically 50 ER alpha 50 subtype selective NMDA receptor 50 geldanamycin 50 renin angiotensin aldosterone 50 pegylated interferons 50 molecularly targeted 50 NR2B 50 BioAstin superior antioxidant 50 Raloxifene STAR 50 angiotensin II receptor 50 mu opioid receptors 50 cholesterol homeostasis 50 nanoviricide 50 ototoxic 50 antiretroviral naïve 50 agonist LABA 50 triterpenoids 50 vivo toxicology 50 progesterone receptor negative 50 Momenta Pharmaceuticals Announces 50 idiopathic PD 50 CB1 receptor 50 ligand receptor 50 Phase Ib II 50 costimulatory molecules 50 opioid receptor antagonist 50 neuroprotectant 50 NADPH oxidase 50 chimeric antibody 50 Kaplan Meier estimate 50 circulating endothelial cells 50 CRp 50 hypothalamic pituitary adrenal HPA 50 selective GR 50 hormone secreted 50 NKT cells 50 GH secretion 50 miRNA expression 50 inhaled bronchodilator 50 mdx mouse 50 NK1 50 Enbrel Remicade 50 CDK8 50 parthenolide 50 neuropeptide Y 50 gastric corpus 50 dorsomedial 50 RQ PCR 50 antidepressive 50 neuroblastoma cells 50 microvessel 50 PDE4 inhibitors 50 bacillus anthracis 50 intramuscular vaccination 50 inhibited tumor 50 pyrimidines 50 Unstable angina 50 plasmids encoding 50 Thrombotic events 50 TNF inhibitor therapy 50 sub maximal 50 pharmacological chaperone 50 microsatellite instability 50 aldose reductase 50 tubulin binding 50 Symptom severity 50 tricuspid regurgitation 50 histologic subtype 50 pheromones molecules 50 quinolone 50 extrapyramidal symptoms EPS 50 FOXO1a 50 highly selective endothelin 50 intracerebral 50 tissue microenvironment 50 underlying pathophysiology 50 PDGF 50 5 HT6 49 hyper responsiveness 49 Hsp# [001] 49 mGluR4 activation 49 upregulated 49 PCI ExTRACT TIMI 49 IGFBP7 49 NEUVENGE 49 refractory colorectal cancer 49 PANVAC VF 49 ocular adverse 49 agonist 49 antisense oligonucleotides 49 oral antidiabetes drugs 49 neuropsychiatric adverse 49 ErbB2 49 Reactive oxygen species 49 secretase 49 TLR agonists 49 Pharmacokinetic analysis 49 GCN2 49 Platinol 49 splenic 49 DGAT 49 PERSEUS 49 androgen receptors 49 excitatory 49 mu opioid receptor 49 autoantigens 49 EGFRIs 49 adrenergic receptors 49 CATIE AD 49 endothelin receptors 49 H#N# mAbs 49 phototoxicity 49 inhibitory receptor 49 Ronald Peleo Lazar 49 transcriptomic 49 quadrivalent human papillomavirus 49 Ets2 49 CaR 49 dexpramipexole 49 fatal anaphylactic 49 depression suicidality 49 glial tumors 49 downregulate 49 ZFN modified cells 49 monoamine 49 inhibiting tumor 49 anticancer agent 49 HMG CoA reductase 49 Abrupt discontinuation 49 complete remissions 49 Phase IIA 49 non steroidal 49 cytotoxic agents 49 bioactive lipid 49 androgen ablation 49 rheumatoid arthritis HUMIRA 49 prolonged cytopenias 49 glandular swelling 49 parkinsonian 49 neuropsychiatric events 49 surgical debulking 49 PPAR 49 osteoclast formation 49 RANKL 49 AMPA kainate 49 affective psychosis 49 Mendendez comments 49 anti androgens 49 AVADO